ProSomnus, Inc.

Equities

OSAPQ

US50535E1082

Advanced Medical Equipment & Technology

Market Closed - OTC Markets 15:32:23 2024-06-14 EDT 5-day change 1st Jan Change
0.01 USD -60.00% Intraday chart for ProSomnus, Inc. -66.67% -98.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Joint Reorganization Plan and Disclosure Statement Filed by ProSomnus, Inc. CI
ProSomnus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Prosomnus Contributes Two Scientific Abstracts Accepted for Presentation At the 2024 American Academy of Dental Sleep Medicine Annual Meeting CI
Interim DIP Financing Approved for ProSomnus, Inc. CI
Motion for Joint Administration Approved for ProSomnus, Inc. CI
Motion for Joint Administration Filed by ProSomnus, Inc. CI
ProSomnus, Inc. Filed for Bankruptcy CI
ProSomnus, Inc.(OTCPK:OSAP) dropped from S&P TMI Index CI
ProSomnus, Inc. announced that it has received $2 million in funding CI
ProSomnus, Inc.(OTCPK:OSAP) dropped from NASDAQ Composite Index CI
Transcript : ProSomnus, Inc., Q4 2023 Earnings Call, Mar 26, 2024
ProSomnus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ProSomnus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Prosomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea CI
ProSomnus, Inc. Severe Indication 510(K) Submission Accepts for Review by the Fda CI
Top Midday Gainers MT
Craig-Hallum Downgrades ProSomnus to Hold From Buy, Cuts Price Target to $1 From $10 MT
ProSomnus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : ProSomnus, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Earnings Flash (OSA) PROSOMNUS SLEEP TECHNOLOGIES Posts Q3 Revenue $7.1M, vs. Street Est of $7.03M MT
Roth MKM Cuts Price Target on ProSomnus to $4 From $6, Maintains Buy Rating MT
ProSomnus, Inc. announced that it expects to receive $25 million in funding from Spring Mountain Capital, LP and other investors CI
Prosomnus, Inc. Announces Updated Clinical Trial Data CI
Transcript : ProSomnus, Inc., Q2 2023 Earnings Call, Aug 03, 2023
ProSomnus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart ProSomnus, Inc.
More charts
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
More about the company
  1. Stock Market
  2. Equities
  3. OSAPQ Stock
  4. News ProSomnus, Inc.
  5. Craig-Hallum Downgrades ProSomnus to Hold From Buy, Cuts Price Target to $1 From $10